1
|
Ferjancic Z, Bihelovic F, Vulovic B, Matovic R, Trmcic M, Jankovic A, Pavlovic M, Djurkovic F, Prodanovic R, Djurdjevic Djelmas A, Kalicanin N, Zlatovic M, Sladic D, Vallet T, Vignuzzi M, Saicic RN. Development of iminosugar-based glycosidase inhibitors as drug candidates for SARS-CoV-2 virus via molecular modelling and in vitro studies. J Enzyme Inhib Med Chem 2024; 39:2289007. [PMID: 38086763 DOI: 10.1080/14756366.2023.2289007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Accepted: 11/24/2023] [Indexed: 12/18/2023] Open
Abstract
We developed new iminosugar-based glycosidase inhibitors against SARS-CoV-2. Known drugs (miglustat, migalastat, miglitol, and swainsonine) were chosen as lead compounds to develop three classes of glycosidase inhibitors (α-glucosidase, α-galactosidase, and mannosidase). Molecular modelling of the lead compounds, synthesis of the compounds with the highest docking scores, enzyme inhibition tests, and in vitro antiviral assays afforded rationally designed inhibitors. Two highly active α-glucosidase inhibitors were discovered, where one of them is the most potent iminosugar-based anti-SARS-CoV-2 agent to date (EC90 = 1.94 µM in A549-ACE2 cells against Omicron BA.1 strain). However, galactosidase inhibitors did not exhibit antiviral activity, whereas mannosidase inhibitors were both active and cytotoxic. As our iminosugar-based drug candidates act by a host-directed mechanism, they should be more resilient to drug resistance. Moreover, this strategy could be extended to identify potential drug candidates for other viral infections.
Collapse
Affiliation(s)
| | - Filip Bihelovic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
| | - Bojan Vulovic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
| | - Radomir Matovic
- University of Belgrade-Institute of Chemistry, Technology and Metallurgy, Belgrade, Serbia
| | - Milena Trmcic
- Innovation Centre of the Faculty of Chemistry, Belgrade, Serbia
| | - Aleksandar Jankovic
- University of Belgrade-Institute of Chemistry, Technology and Metallurgy, Belgrade, Serbia
| | - Milos Pavlovic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
| | - Filip Djurkovic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
| | | | | | - Nevena Kalicanin
- University of Belgrade-Institute of Chemistry, Technology and Metallurgy, Belgrade, Serbia
| | - Mario Zlatovic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
| | - Dusan Sladic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
| | - Thomas Vallet
- Institut Pasteur, Center for the Viral Populations and Pathogenesis, Paris, France
| | - Marco Vignuzzi
- Institut Pasteur, Center for the Viral Populations and Pathogenesis, Paris, France
- A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
| | - Radomir N Saicic
- Faculty of Chemistry, University of Belgrade, Belgrade, Serbia
- Serbian Academy of Sciences and Arts, Belgrade, Serbia
| |
Collapse
|
2
|
Thaler M, Ofman TP, Kok K, Heming JJA, Moran E, Pickles I, Leijs AA, van den Nieuwendijk AMC, van den Berg RJBHN, Ruijgrok G, Armstrong Z, Salgado-Benvindo C, Ninaber DK, Snijder EJ, van Boeckel CAA, Artola M, Davies GJ, Overkleeft HS, van Hemert MJ. Epi-Cyclophellitol Cyclosulfate, a Mechanism-Based Endoplasmic Reticulum α-Glucosidase II Inhibitor, Blocks Replication of SARS-CoV-2 and Other Coronaviruses. ACS CENTRAL SCIENCE 2024; 10:1594-1608. [PMID: 39220688 PMCID: PMC11363342 DOI: 10.1021/acscentsci.4c00506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 07/04/2024] [Accepted: 07/09/2024] [Indexed: 09/04/2024]
Abstract
The combined inhibition of endoplasmic reticulum (ER) α-glucosidases I and II has been shown to inhibit replication of a broad range of viruses that rely on ER protein quality control. We found, by screening a panel of deoxynojirimycin and cyclitol glycomimetics, that the mechanism-based ER α-glucosidase II inhibitor, 1,6-epi-cyclophellitol cyclosulfate, potently blocks SARS-CoV-2 replication in lung epithelial cells, halting intracellular generation of mature spike protein, reducing production of infectious progeny, and leading to reduced syncytium formation. Through activity-based protein profiling, we confirmed ER α-glucosidase II inhibition in primary airway epithelial cells, grown at the air-liquid interface. 1,6-epi-Cyclophellitol cyclosulfate inhibits early pandemic and more recent SARS-CoV-2 variants, as well as SARS-CoV and MERS-CoV. The reported antiviral activity is comparable to the best-in-class described glucosidase inhibitors, all competitive inhibitors also targeting ER α-glucosidase I and other glycoprocessing enzymes not involved in ER protein quality control. We propose selective blocking ER-resident α-glucosidase II in a covalent and irreversible manner as a new strategy in the search for effective antiviral agents targeting SARS-CoV-2 and other viruses that rely on ER protein quality control.
Collapse
Affiliation(s)
- Melissa Thaler
- Leiden
University Center for Infectious Diseases (LUCID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Tim P. Ofman
- Leiden
Institute of Chemistry, Leiden University, 2311 EZ Leiden, The Netherlands
| | - Ken Kok
- Leiden
Institute of Chemistry, Leiden University, 2311 EZ Leiden, The Netherlands
| | | | - Elisha Moran
- Department
of Chemistry, University of York, York YO10 5DD, United Kingdom
| | - Isabelle Pickles
- Department
of Chemistry, University of York, York YO10 5DD, United Kingdom
| | - Anouk A. Leijs
- Leiden
University Center for Infectious Diseases (LUCID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | | | | | - Gijs Ruijgrok
- Leiden
Institute of Chemistry, Leiden University, 2311 EZ Leiden, The Netherlands
| | - Zachary Armstrong
- Leiden
Institute of Chemistry, Leiden University, 2311 EZ Leiden, The Netherlands
| | - Clarisse Salgado-Benvindo
- Leiden
University Center for Infectious Diseases (LUCID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Dennis K. Ninaber
- Department
of Pulmonology, Leiden University Medical
Center, 2333 ZA Leiden, The Netherlands
| | - Eric J. Snijder
- Leiden
University Center for Infectious Diseases (LUCID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | | | - Marta Artola
- Leiden
Institute of Chemistry, Leiden University, 2311 EZ Leiden, The Netherlands
| | - Gideon J. Davies
- Department
of Chemistry, University of York, York YO10 5DD, United Kingdom
| | - Herman S. Overkleeft
- Leiden
Institute of Chemistry, Leiden University, 2311 EZ Leiden, The Netherlands
| | - Martijn J. van Hemert
- Leiden
University Center for Infectious Diseases (LUCID), Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| |
Collapse
|
3
|
Prencipe F, Barzan C, Savian C, Spalluto G, Carosati E, De Amici M, Mosconi G, Gianferrara T, Federico S, Da Ros T. Gaucher Disease: A Glance from a Medicinal Chemistry Perspective. ChemMedChem 2024; 19:e202300641. [PMID: 38329692 DOI: 10.1002/cmdc.202300641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 01/19/2024] [Accepted: 02/07/2024] [Indexed: 02/09/2024]
Abstract
Rare diseases are particular pathological conditions affecting a limited number of people and few drugs are known to be effective as therapeutic treatment. Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, belongs to this class of disorders, and it is considered the most common among the Lysosomal Storage Diseases. The two main therapeutic approaches are the Enzyme Replacement Therapy (ERT) and the Substrate Reduction Therapy (SRT). ERT, consisting in replacing the defective enzyme by administering a recombinant enzyme, is effective in alleviating the visceral symptoms, hallmarks of the most common subtype of the disease whereas it has no effects when symptoms involve CNS, since the recombinant protein is unable to significantly cross the Blood Brain Barrier. The SRT strategy involves inhibiting glucosylceramide synthase (GCS), the enzyme responsible for the production of the associated storage molecule. The rational design of new inhibitors of GCS has been hampered by the lack of either the crystal structure of the enzyme or an in-silico model of the active site which could provide important information regarding the interactions of potential inhibitors with the target, but, despite this, interesting results have been obtained and are herein reviewed.
Collapse
Affiliation(s)
- Filippo Prencipe
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| | - Chiara Barzan
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
- Molecular Genetics Institute, CNR Via Abbiategrasso 207, 27100, Pavia, Italy
| | - Chiara Savian
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| | - Giampiero Spalluto
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| | - Emanuele Carosati
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| | - Marco De Amici
- Department of Pharmaceutical Sciences, University of Milano Via Luigi Mangiagalli 25, 20133, Milano, Italy
| | - Giorgio Mosconi
- Fidia Farmaceutici Via Ponte della Fabbrica 3/A, 35021, Abano Terme, Italy
| | - Teresa Gianferrara
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| | - Stephanie Federico
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| | - Tatiana Da Ros
- Department of Chemical and Pharmaceutical Sciences, University of Trieste, Via Licio Giorgieri 1, 34127, Trieste, Italy
| |
Collapse
|
4
|
Park S, Myeong IS, Ham WH. Recent advances in the total synthesis of polyhydroxylated alkaloids via chiral oxazines. Org Biomol Chem 2024; 22:894-926. [PMID: 38230703 DOI: 10.1039/d3ob01624b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2024]
Abstract
This review summarizes recently established methodologies developed for the enantioselective and diastereoselective synthesis of chiral 1,3-oxazines. These compounds are of interest as advanced synthetic intermediates in the total synthesis of structurally complex and biologically active polyhydroxylated alkaloids such as (+)-1-deoxynojirimycin, (-)-anisomycin, (+)-castanospermine, (+)-casuarine, (-)-conduramine F-1, (-)-sphingofungin B, Neu5Ac methyl ester, and other natural products. The devised synthetic approach aims to offer a direct, efficient, and adaptable method for obtaining both pure enantiomers and pure diastereomers. It revolves around utilizing chiral building blocks like syn,syn-, syn,syn,anti-, syn,anti-, syn,anti,syn-, anti,syn-, anti,syn,syn-, and anti,syn,anti-oxazines. By integrating oxazine chemistry with established and innovative transformations, this approach enabled the synthesis of 30 polyhydroxylated amines across various studies conducted between 2007 and 2022.
Collapse
Affiliation(s)
- Seokhwi Park
- YS Life Science Co., Ltd, 207, Sujeong-ro, Jangan-myeon, Hwaseong-si, Gyeonggi-do, 18581, Republic of Korea.
| | - In-Soo Myeong
- College of Pharmacy, Daegu Catholic University, 13-13, Hayang-ro, Hayang-eup, Gyeongsan-si, Gyeongsangbuk-do, 38430, Republic of Korea.
| | - Won-Hun Ham
- YS Life Science Co., Ltd, 207, Sujeong-ro, Jangan-myeon, Hwaseong-si, Gyeonggi-do, 18581, Republic of Korea.
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Suwon-si, Gyeonggi-do, 16419, Republic of Korea
| |
Collapse
|
5
|
Mistry PK, Kishnani PS, Balwani M, Charrow JM, Hull J, Weinreb NJ, Cox TM. The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158. J Clin Med 2023; 12:jcm12093269. [PMID: 37176709 PMCID: PMC10179580 DOI: 10.3390/jcm12093269] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2023] [Revised: 02/13/2023] [Accepted: 02/17/2023] [Indexed: 05/15/2023] Open
Abstract
In their paper, Hughes et al. [...].
Collapse
Affiliation(s)
- Pramod K Mistry
- Department of Medicine, Pediatrics, and Cellular & Molecular Physiology, Yale University School of Medicine, 20 York Street, New Haven, CT 06510, USA
| | - Priya S Kishnani
- Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
| | - Manisha Balwani
- Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Joel M Charrow
- Division of Genetics, Genomics, and Metabolism, Northwestern University Feinberg School of Medicine, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL 60611, USA
| | - Judy Hull
- Gaucher Disease, US Medical Affairs, Sanofi, Cambridge, MA 02141, USA
| | - Neal J Weinreb
- Department of Human Genetics, University of Miami Miller School of Medicine, Miami, FL 33433, USA
| | - Timothy M Cox
- Lysosomal Disorders Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK
| |
Collapse
|
6
|
Swanson CB, Ford GJ, Mattey AP, Gourbeyre L, Flitsch SL. Biocatalytic Cascades toward Iminosugar Scaffolds Reveal Promiscuous Activity of Shikimate Dehydrogenases. ACS CENTRAL SCIENCE 2023; 9:103-108. [PMID: 36712485 PMCID: PMC9881201 DOI: 10.1021/acscentsci.2c01169] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Indexed: 06/18/2023]
Abstract
Iminosugar scaffolds are highly sought-after pharmaceutical targets, but their chemical synthesis is lengthy and can suffer from poor scalability and purification. Here we report protecting-group-free chemoenzymatic and biocatalytic cascades to synthesize iminosugars from sugar-derived aminopolyols in two steps. Using galactose oxidase variant F2 followed by a chemical or enzymatic reduction provided an efficient one-pot route to these targets, with product formation >70%. Key to success of this strategy was the application of genome mining, which identified bacterial shikimate dehydrogenases as promiscuous iminosugar reductases. The cell-free protocols allowed for isolation of highly polar iminosugar products from biotransformations in a single step through development of a gradient-elution cation exchange purification. The two-step pathway provides a short synthetic route that can be used as a cell-free platform for broader iminosugar synthesis.
Collapse
|
7
|
Inhibitors of Glucosylceramide Synthase. Methods Mol Biol 2023; 2613:271-288. [PMID: 36587085 DOI: 10.1007/978-1-0716-2910-9_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Glucosylceramide synthase can be targeted by high affinity small molecular weight inhibitors for the study of glycosphingolipid metabolism and function or for the treatment of glycosphingolipid storage disorders, including Gaucher and Fabry disease. This work is exemplified by the discovery and development of eliglustat tartrate, the first stand-alone small chemical entity approved for the treatment of Gaucher disease type 1. The development of inhibitors of glucosylceramide synthase that have utility for either research or clinical purposes begins with a testing funnel for screening candidate inhibitors for activity against this enzyme and for activity in lowering the content of glucosylceramide in intact cells. Two common assays for glucosylceramide synthase, one enzyme based and another cell based, are the focus of this chapter.
Collapse
|
8
|
Kotian PL, Wu M, Ghosh A, Polach KJ, El-Kattan Y, Kumar VS, Lin TH, Cheng X, Bantia S, Raman K, Chand P, Babu YS. Synthesis of novel azasugar-containing 2'β-C-Me 9-deaza nucleosides as potential anti-hepatitis C virus agents. NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS 2023; 42:317-327. [PMID: 36354089 DOI: 10.1080/15257770.2022.2142609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
As a part of our ongoing discovery efforts exploring azasugar as agents for treating various unmet medical needs, we prepared analogs of azasugar as potential anti-hepatitis C virus (HCV) agents. Herein we describe the synthesis of novel 2'β-C-Me 9-deazanucleoside azasugar analogs.
Collapse
Affiliation(s)
- Pravin L Kotian
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Minwan Wu
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Ajit Ghosh
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Kevin J Polach
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Yahya El-Kattan
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - V Satish Kumar
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Tsu-Hsing Lin
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Xiaogang Cheng
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Shanta Bantia
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Krishnan Raman
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Pooran Chand
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| | - Yarlagadda S Babu
- BioCryst Pharmaceuticals, Inc, 2100 Riverchase Center, Building 200, Suite 200, Birmingham, AL, 35244, USA
| |
Collapse
|
9
|
Chand HR, Tiwari MK, Bhattacharya AK. Glycal mediated synthesis of piperidine alkaloids: fagomine, 4- epi-fagomine, 2-deoxynojirimycin, and an advanced intermediate, iminoglycal. RSC Adv 2022; 12:33021-33031. [PMID: 36425185 PMCID: PMC9670682 DOI: 10.1039/d2ra05224e] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Accepted: 10/26/2022] [Indexed: 12/09/2023] Open
Abstract
Glucal and galactal are transformed into 2-deoxyglycolactams, which are important building blocks in the synthesis of biologically active piperidine alkaloids, fagomine and 4-epi-fagomine. In one of the strategies, reduction of 2-deoxyglycolactam-N-Boc carbonyl by lithium triethylborohydride (Super-Hydride®) has been exploited to generate lactamol whereas reduction followed by dehydration was utilized as the other strategy to functionalize the C1-C2 bond in the iminosugar substrate. The strategies provide the formal synthesis of 2-deoxynojirimycin, nojirimycin and nojirimycin B. DFT studies were carried out to determine the reason for the failure of the formation of the 2-deoxygalactonojirimycin derivative. Further, DFT studies suggest that phenyl moieties of protecting groups and lone pairs of oxygen in carbamate group plays a vital role in deciphering the conformational space of the reaction intermediates and transition-state structures through cation-π or cation-lone pair interactions. The influence of these interactions is more pronounced at low temperature when the entropy factor is small.
Collapse
Affiliation(s)
- Hemender R Chand
- Division of Organic Chemistry, CSIR-National Chemical Laboratory Dr Homi Bhabha Road, Pashan Pune 411008 Maharashtra India
| | - Mritunjay K Tiwari
- Physical and Material Chemistry Division, CSIR-National Chemical Laboratory Dr Homi Bhabha Road, Pashan Pune 411008 Maharashtra India
| | - Asish K Bhattacharya
- Division of Organic Chemistry, CSIR-National Chemical Laboratory Dr Homi Bhabha Road, Pashan Pune 411008 Maharashtra India
- Academy of Scientific and Innovative Research (AcSIR) Ghaziabad India
| |
Collapse
|
10
|
Qu Z, Zhou L. Drug Development in the Field of Sphinogolipid Metabolism. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2022; 1372:169-188. [DOI: 10.1007/978-981-19-0394-6_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Fujii T, Tanaka Y, Oki H, Sato S, Shibata S, Maru T, Tanaka Y, Tanaka M, Onishi T. A new brain-penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher disease. J Neurochem 2021; 159:543-553. [PMID: 34398463 PMCID: PMC9293090 DOI: 10.1111/jnc.15492] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Revised: 07/30/2021] [Accepted: 08/11/2021] [Indexed: 11/26/2022]
Abstract
Gaucher disease (GD), the most common lysosomal storage disorders, is caused by GBA gene mutations resulting in glycosphingolipids accumulations in various tissues, such as the brain. While suppressing glycosphingolipid accumulation is the central strategy for treating peripheral symptoms of GD, there is no effective treatment for the central nervous system symptoms. As glycosphingolipid biosynthesis starts from ceramide glycosylation by glucosylceramide synthase (GCS), inhibiting GCS in the brain is a promising strategy for neurological GD. Herein, we discovered T-036, a potent and brain-penetrant GCS inhibitor with a unique chemical structure and binding property. T-036 does not harbor an aliphatic amine moiety and has a noncompetitive inhibition mode to the substrates, unlike other known inhibitors. T-036 exhibited sufficient exposure and a significant reduction of glucosylsphingolipids in the plasma and brain of the GD mouse model. Therefore, T-036 could be a promising lead molecule for treating central nervous system symptoms of GD.
Collapse
Affiliation(s)
- Takahiro Fujii
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Yuta Tanaka
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Hideyuki Oki
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Sho Sato
- Drug Metabolism and Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Sachio Shibata
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Takamitsu Maru
- Discovery Biology, Discovery Science, Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa, Japan
| | - Yuta Tanaka
- Drug Discovery Sciences, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Maiko Tanaka
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | - Tomohiro Onishi
- Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| |
Collapse
|
12
|
Abstract
Iminosugars are naturally occurring carbohydrate analogues known since 1967. These natural compounds and hundreds of their synthetic derivatives prepared over five decades have been mainly exploited to inhibit the glycosidases, the enzymes catalysing the glycosidic bond cleavage, in order to find new drugs for the treatment of type 2 diabetes and other diseases. However, iminosugars are also inhibitors of glycosyltransferases, the enzymes responsible for the synthesis of oligosaccharides and glycoconjugates. The selective inhibition of specific glycosyltransferases involved in cancer or bacterial infections could lead to innovative therapeutic agents. The synthesis and biological properties of all the iminosugars assayed to date as glycosyltransferase inhibitors are reviewed in the present article.
Collapse
Affiliation(s)
- Irene Conforti
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier, 8 Rue de l'Ecole Normale, 34296 Montpellier cedex 5, France.
| | - Alberto Marra
- Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, Ecole Nationale Supérieure de Chimie de Montpellier, 8 Rue de l'Ecole Normale, 34296 Montpellier cedex 5, France.
| |
Collapse
|
13
|
Iftikhar M, Lu Y, Zhou M. An overview of therapeutic potential of N-alkylated 1-deoxynojirimycin congeners. Carbohydr Res 2021; 504:108317. [PMID: 33932806 DOI: 10.1016/j.carres.2021.108317] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Revised: 04/12/2021] [Accepted: 04/12/2021] [Indexed: 01/13/2023]
Abstract
Polyhydroxylated alkaloids display a wide range of biological activities, suggesting their use in the treatment of various diseases. Their most famous representative, 1-deoxynojirimycin (DNJ), is a natural product that shows α- and β-glucosidase inhibition. This molecule has been since converted into two clinically approved drugs i.e., Zavesca® and Glyset®, targeting type I Gaucher's disease and type II diabetes mellitus, respectively. This review examines the therapeutic potential of important DNJ congeners reported in last decade and presents concise mechanism of glycosidase inhibition. A brief overview of substituents conjugation's impact on DNJ scaffold (including N-alkylated DNJ derivatives, mono-valent, di-valent and multivalent DNJ congeners, N-[5-(adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin (AMP-DNM) look alike DNJ based lipophilic derivatives, AMP-DNM based neoglycoconjugates, DNJ click derivatives with varying carboxylic acids and aromatic moieties, conjugates of DNJ and glucose, and N-bridged DNJ analogues) towards various enzymes such as α/β glucosidase, porcine trehalase, as F508del-CFTR correctors, α-mannosidase, human placental β-glucocerebrosidase, N370S β-GCase, α-amylase and insect trehalase as potent and selective inhibitors have been discussed with potential bioactivities, which can provide inspiration for future studies.
Collapse
Affiliation(s)
- Mehwish Iftikhar
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu, 210094, PR China
| | - Yinghong Lu
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu, 210094, PR China
| | - Min Zhou
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu, 210094, PR China.
| |
Collapse
|
14
|
Stereodivergent synthesis of piperidine iminosugars 1-deoxy-D-nojirimycin and 1-deoxy-D-altronojirimycin. Tetrahedron 2021. [DOI: 10.1016/j.tet.2020.131837] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
15
|
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis. Int J Mol Sci 2020; 21:ijms21093353. [PMID: 32397443 PMCID: PMC7247015 DOI: 10.3390/ijms21093353] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 05/06/2020] [Accepted: 05/06/2020] [Indexed: 12/13/2022] Open
Abstract
Iminosugars are sugar analogues endowed with a high pharmacological potential. The wide range of biological activities exhibited by these glycomimetics associated with their excellent drug profile make them attractive therapeutic candidates for several medical interventions. The ability of iminosugars to act as inhibitors or enhancers of carbohydrate-processing enzymes suggests their potential use as therapeutics for the treatment of cystic fibrosis (CF). Herein we review the most relevant advances in the field, paying attention to both the chemical synthesis of the iminosugars and their biological evaluations, resulting from in vitro and in vivo assays. Starting from the example of the marketed drug NBDNJ (N-butyl deoxynojirimycin), a variety of iminosugars have exhibited the capacity to rescue the trafficking of F508del-CFTR (deletion of F508 residue in the CF transmembrane conductance regulator), either alone or in combination with other correctors. Interesting results have also been obtained when iminosugars were considered as anti-inflammatory agents in CF lung disease. The data herein reported demonstrate that iminosugars hold considerable potential to be applied for both therapeutic purposes.
Collapse
|
16
|
Yang LF, Shimadate Y, Kato A, Li YX, Jia YM, Fleet GWJ, Yu CY. Synthesis and glycosidase inhibition of N-substituted derivatives of 1,4-dideoxy-1,4-imino-d-mannitol (DIM). Org Biomol Chem 2020; 18:999-1011. [DOI: 10.1039/c9ob02029b] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Four series of N-substituted DIMs have been synthesized and assayed against glycosidases to provide continuous and reliable inhibitory spectra.
Collapse
Affiliation(s)
- Lin-Feng Yang
- Beijing National Laboratory for Molecular Science (BNLMS)
- CAS Key Laboratory of Molecular Recognition and Function
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190
| | - Yuna Shimadate
- Department of Hospital Pharmacy
- University of Toyama
- Toyama 930-0194
- Japan
| | - Atsushi Kato
- Department of Hospital Pharmacy
- University of Toyama
- Toyama 930-0194
- Japan
| | - Yi-Xian Li
- Beijing National Laboratory for Molecular Science (BNLMS)
- CAS Key Laboratory of Molecular Recognition and Function
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190
| | - Yue-Mei Jia
- Beijing National Laboratory for Molecular Science (BNLMS)
- CAS Key Laboratory of Molecular Recognition and Function
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190
| | - George W. J. Fleet
- Chemistry Research Laboratory
- Department of Chemistry
- University of Oxford
- Oxford
- UK
| | - Chu-Yi Yu
- Beijing National Laboratory for Molecular Science (BNLMS)
- CAS Key Laboratory of Molecular Recognition and Function
- Institute of Chemistry
- Chinese Academy of Sciences
- Beijing 100190
| |
Collapse
|
17
|
N-Butyldeoxygalactonojirimycin Induces Reversible Infertility in Male CD Rats. Int J Mol Sci 2019; 21:ijms21010301. [PMID: 31906257 PMCID: PMC6982022 DOI: 10.3390/ijms21010301] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Revised: 12/17/2019] [Accepted: 12/30/2019] [Indexed: 12/21/2022] Open
Abstract
This study shows for the first time that an iminosugar exerts anti-spermiogenic effect, inducing reversible infertility in a species that is not related to C57BL/6 male mice. In CD rats, N-butyldeoxygalactonojirimycin (NB-DGJ) caused reversible infertility at 150 mg/kg/day when administered daily as single oral dose. NB-DGJ inhibited CD rat-derived testicular β-glucosidase 2 (GBA2) activity at 10 µM but did not inhibit CD rat-derived testicular ceramide-specific glucosyltransferase (CGT) at doses up to 1000 µM. Pharmacokinetic studies revealed that sufficient plasma levels of NB-DGJ (50 µM) were achieved to inhibit the enzyme. Fertility was blocked after 35 days of treatment and reversed one week after termination of treatment. The rapid return of fertility indicates that the major effect of NB-DGJ may be epididymal rather than testicular. Collectively, our in vitro and in vivo studies in rats suggest that iminosugars should continue to be pursued as potential lead compounds for development of oral, non-hormonal male contraceptives. The study also adds evidence that GBA2, and not CGT, is the major target for the contraceptive effect of iminosugars.
Collapse
|
18
|
Aerts JMFG, Artola M, van Eijk M, Ferraz MJ, Boot RG. Glycosphingolipids and Infection. Potential New Therapeutic Avenues. Front Cell Dev Biol 2019; 7:324. [PMID: 31867330 PMCID: PMC6908816 DOI: 10.3389/fcell.2019.00324] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 11/25/2019] [Indexed: 12/13/2022] Open
Abstract
Glycosphingolipids (GSLs), the main topic of this review, are a subclass of sphingolipids. With their glycans exposed to the extracellular space, glycosphingolipids are ubiquitous components of the plasma membrane of cells. GSLs are implicated in a variety of biological processes including specific infections. Several pathogens use GSLs at the surface of host cells as binding receptors. In addition, lipid-rafts in the plasma membrane of host cells may act as platform for signaling the presence of pathogens. Relatively common in man are inherited deficiencies in lysosomal glycosidases involved in the turnover of GSLs. The associated storage disorders (glycosphingolipidoses) show lysosomal accumulation of substrate(s) of the deficient enzyme. In recent years compounds have been identified that allow modulation of GSLs levels in cells. Some of these agents are well tolerated and already used to treat lysosomal glycosphingolipidoses. This review summarizes present knowledge on the role of GSLs in infection and subsequent immune response. It concludes with the thought to apply glycosphingolipid-lowering agents to prevent and/or combat infections.
Collapse
Affiliation(s)
| | - M Artola
- Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
| | - M van Eijk
- Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
| | - M J Ferraz
- Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
| | - R G Boot
- Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands
| |
Collapse
|
19
|
Herrera Moro Chao D, Wang Y, Foppen E, Ottenhoff R, van Roomen C, Parlevliet ET, van Eijk M, Verhoek M, Boot R, Marques AR, Scheij S, Mirzaian M, Kooijman S, Jansen K, Wang D, Mergen C, Seeley RJ, Tschöp MH, Overkleeft H, Rensen PCN, Kalsbeek A, Aerts JMFG, Yi CX. The Iminosugar AMP-DNM Improves Satiety and Activates Brown Adipose Tissue Through GLP1. Diabetes 2019; 68:2223-2234. [PMID: 31578192 DOI: 10.2337/db19-0049] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2019] [Accepted: 09/21/2019] [Indexed: 12/28/2022]
Abstract
Obesity is taking on worldwide epidemic proportions, yet effective pharmacological agents with long-term efficacy remain unavailable. Previously, we designed the iminosugar N-adamantine-methyloxypentyl-deoxynojirimycin (AMP-DNM), which potently improves glucose homeostasis by lowering excessive glycosphingolipids. Here we show that AMP-DNM promotes satiety and activates brown adipose tissue (BAT) in obese rodents. Moreover, we demonstrate that the mechanism mediating these favorable actions depends on oral, but not central, administration of AMP-DNM, which ultimately stimulates systemic glucagon-like peptide 1 (GLP1) secretion. We evidence an essential role of brain GLP1 receptors (GLP1r), as AMP-DNM fails to promote satiety and activate BAT in mice lacking the brain GLP1r as well as in mice treated intracerebroventricularly with GLP1r antagonist exendin-9. In conclusion, AMP-DNM markedly ameliorates metabolic abnormalities in obese rodents by restoring satiety and activating BAT through central GLP1r, while improving glucose homeostasis by mechanisms independent of central GLP1r.
Collapse
Affiliation(s)
- Daniela Herrera Moro Chao
- Department of Medical Biochemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
- Laboratory of Endocrinology, Department of Endocrinology and Metabolism, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Yanan Wang
- Division of Endocrinology and Einthoven Laboratory for Experimental Vascular Medicine, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Ewout Foppen
- Laboratory of Endocrinology, Department of Endocrinology and Metabolism, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Roelof Ottenhoff
- Department of Medical Biochemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Cindy van Roomen
- Department of Medical Biochemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Edwin T Parlevliet
- Division of Endocrinology and Einthoven Laboratory for Experimental Vascular Medicine, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Marco van Eijk
- Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Marri Verhoek
- Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Rolf Boot
- Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Andre R Marques
- Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Saskia Scheij
- Department of Medical Biochemistry, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Mina Mirzaian
- Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Sander Kooijman
- Division of Endocrinology and Einthoven Laboratory for Experimental Vascular Medicine, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Kirstin Jansen
- Laboratory of Endocrinology, Department of Endocrinology and Metabolism, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Dawei Wang
- Hypothalamic Integration Mechanisms, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands
- Institute of Plant Protection, Chinese Academy of Agricultural Science, Beijing, China
| | - Clarita Mergen
- Helmholtz Diabetes Center and German Center for Diabetes Research, Helmholtz Zentrum München, Neuherberg, Germany, and Division of Metabolic Diseases, Technische Universität München, Munich, Germany
| | | | - Matthias H Tschöp
- Helmholtz Diabetes Center and German Center for Diabetes Research, Helmholtz Zentrum München, Neuherberg, Germany, and Division of Metabolic Diseases, Technische Universität München, Munich, Germany
| | - Herman Overkleeft
- Department of Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Patrick C N Rensen
- Division of Endocrinology and Einthoven Laboratory for Experimental Vascular Medicine, Department of Medicine, Leiden University Medical Center, Leiden, the Netherlands
| | - Andries Kalsbeek
- Laboratory of Endocrinology, Department of Endocrinology and Metabolism, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
- Hypothalamic Integration Mechanisms, Netherlands Institute for Neuroscience, Amsterdam, the Netherlands
| | - Johannes M F G Aerts
- Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden, the Netherlands
| | - Chun-Xia Yi
- Laboratory of Endocrinology, Department of Endocrinology and Metabolism, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|
20
|
Lelieveld LT, Mirzaian M, Kuo CL, Artola M, Ferraz MJ, Peter REA, Akiyama H, Greimel P, van den Berg RJBHN, Overkleeft HS, Boot RG, Meijer AH, Aerts JMFG. Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish. J Lipid Res 2019; 60:1851-1867. [PMID: 31562193 DOI: 10.1194/jlr.ra119000154] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 09/24/2019] [Indexed: 11/20/2022] Open
Abstract
β-glucosidases [GBA1 (glucocerebrosidase) and GBA2] are ubiquitous essential enzymes. Lysosomal GBA1 and cytosol-facing GBA2 degrade glucosylceramide (GlcCer); GBA1 deficiency causes Gaucher disease, a lysosomal storage disorder characterized by lysosomal accumulation of GlcCer, which is partly converted to glucosylsphingosine (GlcSph). GBA1 and GBA2 also may transfer glucose from GlcCer to cholesterol, yielding glucosylated cholesterol (GlcChol). Here, we aimed to clarify the role of zebrafish Gba2 in glycosphingolipid metabolism during Gba1 deficiency in zebrafish (Danio rerio), which are able to survive total Gba1 deficiency. We developed Gba1 (gba1 -/-), Gba2 (gba2 -/-), and double (gba1 -/- :gba2 -/-) zebrafish knockouts using CRISPR/Cas9 and explored the effects of both genetic and pharmacological interventions on GlcCer metabolism in individual larvae. Activity-based probes and quantification of relevant glycolipid metabolites confirmed enzyme deficiency. GlcSph increased in gba1 -/- larvae (0.09 pmol/fish) but did not increase more in gba1 -/- :gba2 -/- larvae. GlcCer was comparable in gba1 -/- and WT larvae but increased in gba2 -/- and gba1 -/- :gba2 -/- larvae. Independent of Gba1 status, GlcChol was low in all gba2 -/- larvae (0.05 vs. 0.18 pmol/fish in WT). Pharmacologic inactivation of zebrafish Gba1 comparably increased GlcSph. Inhibition of GlcCer synthase (GCS) in Gba1-deficient larvae reduced GlcCer and GlcSph, and concomitant inhibition of GCS and Gba2 with iminosugars also reduced excessive GlcChol. Finally, overexpression of human GBA1 and injection of recombinant GBA1 both decreased GlcSph. We determined that zebrafish larvae offer an attractive model to study glucosidase actions in glycosphingolipid metabolism in vivo, and we identified distinguishing characteristics of zebrafish Gba2 deficiency.
Collapse
Affiliation(s)
- Lindsey T Lelieveld
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Mina Mirzaian
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Chi-Lin Kuo
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Marta Artola
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands.,Bio-organic Synthesis Group, Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Maria J Ferraz
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Remco E A Peter
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| | | | | | | | - Herman S Overkleeft
- Bio-organic Synthesis Group, Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Rolf G Boot
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| | | | - Johannes M F G Aerts
- Department of Medical Biochemistry Leiden Institute of Chemistry, Leiden, The Netherlands
| |
Collapse
|
21
|
Peterschmitt MJ, Freisens S, Underhill LH, Foster MC, Lewis G, Gaemers SJM. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1. Orphanet J Rare Dis 2019; 14:128. [PMID: 31174576 PMCID: PMC6555985 DOI: 10.1186/s13023-019-1085-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 04/29/2019] [Indexed: 11/17/2022] Open
Abstract
Background Eliglustat is a first-line oral treatment for adults with Gaucher disease type 1 who have an extensive, intermediate or poor CYP2D6 metabolizer phenotype (> 90% of patients). Whereas enzyme replacement therapy for Gaucher disease has been widely used for more than two decades, eliglustat has only been in commercial use since 2014. Clinicians and patients want to better understand which adverse events are most commonly associated with eliglustat, as well as their severity, frequency, and duration. Methods This pooled analysis of treatment-emergent adverse events combines data from four completed eliglustat clinical trials involving 393 Gaucher disease type 1 patients. It represents 1400 patient-years of eliglustat exposure and a mean treatment duration of 3.6 years (maximum: 9.3 years). Results Eighty-one percent of patients remained in their respective trial until commercial availability of eliglustat (US patients only) or until trial completion. Nine patients (2.3%) withdrew from their respective trial due to one or more adverse events reported as eliglustat treatment-related; all but one of these events were mild or moderate. Overall, 97% of adverse events were mild or moderate and 86% were reported by the investigator as unrelated to eliglustat treatment. The overall rate of adverse events decreased over time and did not increase with increasing eliglustat dose. We evaluated frequency, duration, and severity of 14 adverse event terms reported at least once as treatment-related in 2% or more of all patients: dyspepsia (5.9%), headache (5.3%), abdominal pain upper (5.1%), dizziness (5.1%), diarrhea (4.6%), nausea (4.6%), arthralgia (3.6%), constipation (3.3%), abdominal pain (2.8%), gastroesophageal reflux disease (2.8%), fatigue (2.8%), palpitations (2.8%), abdominal distension (2.5%), and gastritis (2.3%). For abdominal pain upper, diarrhea, nausea, abdominal pain, and headache events, median duration was less than 14 days. All 14 adverse event terms, except for arthralgia and headache, were reported only once per patient in more than 70% of patients experiencing the event. Conclusions This final pooled analysis of treatment-emergent adverse events reinforces the favorable safety profile of eliglustat. The majority of the most frequently reported treatment-related adverse events were mild or moderate, transient, and occurred only once per patient. Electronic supplementary material The online version of this article (10.1186/s13023-019-1085-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | | | | | | | - Grace Lewis
- Sanofi Genzyme, Cambridge, Massachusetts, United States
| | | |
Collapse
|
22
|
Harzer K, Yildiz Y, Beck-Wödl S. Assay of β-glucosidase 2 (GBA2) activity using lithocholic acid β-3-O-glucoside substrate for cultured fibroblasts and glucosylceramide for brain tissue. Biol Chem 2019; 400:745-752. [PMID: 30864417 DOI: 10.1515/hsz-2018-0438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 11/27/2018] [Indexed: 11/15/2022]
Abstract
Beta (β)-glucosidase 2 (GBA2) is deficient in a form of human spastic paraplegia due to defects in GBA2 (SPG46). GBA2 was proposed as a modifier of Gaucher disease, a lysosomal storage disease resulting from deficient β-glucosidase 1; GBA1. Current GBA2 activity assays using artificial substrates incompletely model the activity encountered in vivo. We studied GBA2 activity, using lithocholic acid β-glucoside or glucosylceramide as natural β-glucosidase substrates in murine tissues or cultured patient fibroblasts with the pathologic genotypes: Gba1-/-; Gba2-/-; GBA1-/-; GBA2+/- and found expected and unexpected deviations from normal controls.
Collapse
Affiliation(s)
- Klaus Harzer
- Department of Neuropediadrics, Neurometabolic Laboratory, Children's Hospital, University of Tübingen, Hoppe-Seyler-Str. 1, D-72076 Tübingen, Germany
| | - Yildiz Yildiz
- Internal Medicine, Medicnova Hospital, Selemad 10, FL-9487 Gamprin-Bendern, Liechtenstein
| | - Stefanie Beck-Wödl
- Department of Medical Genetics and Applied Genomics, University of Tübingen, Calwerstr. 7, D-72076 Tübingen, Germany
| |
Collapse
|
23
|
De Fenza M, D'Alonzo D, Esposito A, Munari S, Loberto N, Santangelo A, Lampronti I, Tamanini A, Rossi A, Ranucci S, De Fino I, Bragonzi A, Aureli M, Bassi R, Tironi M, Lippi G, Gambari R, Cabrini G, Palumbo G, Dechecchi MC, Guaragna A. Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease. Eur J Med Chem 2019; 175:63-71. [PMID: 31075609 DOI: 10.1016/j.ejmech.2019.04.061] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 04/04/2019] [Accepted: 04/21/2019] [Indexed: 12/28/2022]
Abstract
In the frame of a research program aimed to explore the relationship between chirality of iminosugars and their therapeutic potential, herein we report the synthesis of N-akyl l-deoxyiminosugars and the evaluation of the anti-inflammatory properties of selected candidates for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) lung disease. Target glycomimetics were prepared by the shortest and most convenient approach reported to date, relying on the use of the well-known PS-TPP/I2 reagent system to prepare reactive alkoxyalkyl iodides, acting as key intermediates. Iminosugars ent-1-3 demonstrated to efficiently reduce the inflammatory response induced by P. aeruginosa in CuFi cells, either alone or in synergistic combination with their d-enantiomers, by selectively inhibiting NLGase. Surprisingly, the evaluation in murine models of lung disease showed that the amount of ent-1 required to reduce the recruitment of neutrophils was 40-fold lower than that of the corresponding d-enantiomer. The remarkably low dosage of the l-iminosugar, combined with its inability to act as inhibitor for most glycosidases, is expected to limit the onset of undesired effects, which are typically associated with the administration of its d-counterpart. Biological results herein obtained place ent-1 and congeners among the earliest examples of l-iminosugars acting as anti-inflammatory agents for therapeutic applications in Cystic Fibrosis.
Collapse
Affiliation(s)
- Maria De Fenza
- Department of Chemical Sciences, University of Napoli Federico II, via Cintia, 80126 Napoli, Italy
| | - Daniele D'Alonzo
- Department of Chemical Sciences, University of Napoli Federico II, via Cintia, 80126 Napoli, Italy.
| | - Anna Esposito
- Department of Chemical Sciences, University of Napoli Federico II, via Cintia, 80126 Napoli, Italy
| | - Silvia Munari
- Laboratory of Molecular Pathology-Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Nicoletta Loberto
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Alessandra Santangelo
- Laboratory of Molecular Pathology-Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Ilaria Lampronti
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
| | - Anna Tamanini
- Laboratory of Molecular Pathology-Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Alice Rossi
- CFaCore, Infection and CF Unit, San Raffaele Scientific Institute, Milano, Italy
| | - Serena Ranucci
- CFaCore, Infection and CF Unit, San Raffaele Scientific Institute, Milano, Italy
| | - Ida De Fino
- CFaCore, Infection and CF Unit, San Raffaele Scientific Institute, Milano, Italy
| | - Alessandra Bragonzi
- CFaCore, Infection and CF Unit, San Raffaele Scientific Institute, Milano, Italy
| | - Massimo Aureli
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Rosaria Bassi
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Matteo Tironi
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Giuseppe Lippi
- Laboratory of Molecular Pathology-Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Roberto Gambari
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
| | - Giulio Cabrini
- Laboratory of Molecular Pathology-Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Giovanni Palumbo
- Department of Chemical Sciences, University of Napoli Federico II, via Cintia, 80126 Napoli, Italy
| | - Maria Cristina Dechecchi
- Laboratory of Molecular Pathology-Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy.
| | - Annalisa Guaragna
- Department of Chemical Sciences, University of Napoli Federico II, via Cintia, 80126 Napoli, Italy
| |
Collapse
|
24
|
Liu B, van Mechelen J, van den Berg RJBHN, van den Nieuwendijk AMCH, Aerts JMFG, van der Marel GA, Codée JDC, Overkleeft HS. Synthesis of Glycosylated 1-Deoxynojirimycins Starting from Natural and Synthetic Disaccharides. European J Org Chem 2018. [DOI: 10.1002/ejoc.201801461] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Bing Liu
- Bioorganic Synthesis; Leiden Institute of Chemistry; Leiden University; Einsteinweg 55 2333 CC Leiden The Netherlands
| | - Jeanine van Mechelen
- Bioorganic Synthesis; Leiden Institute of Chemistry; Leiden University; Einsteinweg 55 2333 CC Leiden The Netherlands
| | | | | | - Johannes M. F. G. Aerts
- Medical Biochemistry; Leiden Institute of Chemistry; Leiden University; Einsteinweg 55 2333 CC Leiden The Netherlands
| | - Gijsbert A. van der Marel
- Bioorganic Synthesis; Leiden Institute of Chemistry; Leiden University; Einsteinweg 55 2333 CC Leiden The Netherlands
| | - Jeroen D. C. Codée
- Bioorganic Synthesis; Leiden Institute of Chemistry; Leiden University; Einsteinweg 55 2333 CC Leiden The Netherlands
| | - Herman S. Overkleeft
- Bioorganic Synthesis; Leiden Institute of Chemistry; Leiden University; Einsteinweg 55 2333 CC Leiden The Netherlands
| |
Collapse
|
25
|
Ben Bdira F, Artola M, Overkleeft HS, Ubbink M, Aerts JMFG. Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses. J Lipid Res 2018; 59:2262-2276. [PMID: 30279220 PMCID: PMC6277158 DOI: 10.1194/jlr.r086629] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Revised: 09/04/2018] [Indexed: 12/12/2022] Open
Abstract
Glycosyl hydrolases (GHs) are carbohydrate-active enzymes that hydrolyze a specific β-glycosidic bond in glycoconjugate substrates; β-glucosidases degrade glucosylceramide, a ubiquitous glycosphingolipid. GHs are grouped into structurally similar families that themselves can be grouped into clans. GH1, GH5, and GH30 glycosidases belong to clan A hydrolases with a catalytic (β/α)8 TIM barrel domain, whereas GH116 belongs to clan O with a catalytic (α/α)6 domain. In humans, GH abnormalities underlie metabolic diseases. The lysosomal enzyme glucocerebrosidase (family GH30), deficient in Gaucher disease and implicated in Parkinson disease etiology, and the cytosol-facing membrane-bound glucosylceramidase (family GH116) remove the terminal glucose from the ceramide lipid moiety. Here, we compare enzyme differences in fold, action, dynamics, and catalytic domain stabilization by binding site occupancy. We also explore other glycosidases with reported glycosylceramidase activity, including human cytosolic β-glucosidase, intestinal lactase-phlorizin hydrolase, and lysosomal galactosylceramidase. Last, we describe the successful translation of research to practice: recombinant glycosidases and glucosylceramide metabolism modulators are approved drug products (enzyme replacement therapies). Activity-based probes now facilitate the diagnosis of enzyme deficiency and screening for compounds that interact with the catalytic pocket of glycosidases. Future research may deepen the understanding of the functional variety of these enzymes and their therapeutic potential.
Collapse
Affiliation(s)
- Fredj Ben Bdira
- Departments of Macromolecular Biochemistry,Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Marta Artola
- Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Herman S Overkleeft
- Bio-organic Synthesis, Leiden Institute of Chemistry, Leiden, The Netherlands
| | - Marcellus Ubbink
- Departments of Macromolecular Biochemistry,Leiden Institute of Chemistry, Leiden, The Netherlands
| | | |
Collapse
|
26
|
Rugen MD, Vernet MMJL, Hantouti L, Soenens A, Andriotis VME, Rejzek M, Brett P, van den Berg RJBHN, Aerts JMFG, Overkleeft HS, Field RA. A chemical genetic screen reveals that iminosugar inhibitors of plant glucosylceramide synthase inhibit root growth in Arabidopsis and cereals. Sci Rep 2018; 8:16421. [PMID: 30401902 PMCID: PMC6219604 DOI: 10.1038/s41598-018-34749-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 10/19/2018] [Indexed: 01/11/2023] Open
Abstract
Iminosugars are carbohydrate mimics that are useful as molecular probes to dissect metabolism in plants. To analyse the effects of iminosugar derivatives on germination and seedling growth, we screened a library of 390 N-substituted iminosugar analogues against Arabidopsis and the small cereal Eragrostis tef (Tef). The most potent compound identified in both systems, N-5-(adamantane-1-yl-ethoxy)pentyl- L-ido-deoxynojirimycin (L-ido-AEP-DNJ), inhibited root growth in agar plate assays by 92% and 96% in Arabidopsis and Tef respectively, at 10 µM concentration. Phenocopying the effect of L-ido-AEP-DNJ with the commercial inhibitor (PDMP) implicated glucosylceramide synthase as the target responsible for root growth inhibition. L-ido-AEP-DNJ was twenty-fold more potent than PDMP. Liquid chromatography-mass spectrometry (LC-MS) analysis of ceramide:glucosylceramide ratios in inhibitor-treated Arabidopsis seedlings showed a decrease in the relative quantity of the latter, confirming that glucosylceramide synthesis is perturbed in inhibitor-treated plants. Bioinformatic analysis of glucosylceramide synthase indicates gene conservation across higher plants. Previous T-DNA insertional inactivation of glucosylceramide synthase in Arabidopsis caused seedling lethality, indicating a role in growth and development. The compounds identified herein represent chemical alternatives that can overcome issues caused by genetic intervention. These inhibitors offer the potential to dissect the roles of glucosylceramides in polyploid crop species.
Collapse
Affiliation(s)
- Michael D Rugen
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
| | - Mathieu M J L Vernet
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
| | - Laila Hantouti
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
| | - Amalia Soenens
- Department of Metabolic Biology, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
- Centro de Biotecnología y Genómica de Plantas, Universidad Politécnica de Madrid-Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Pozuelo de Alarcón, Madrid, Spain
| | - Vasilios M E Andriotis
- Department of Metabolic Biology, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
- School of Natural and Environmental Sciences, Devonshire Building, Newcastle University, Newcastle-upon-Tyne, NE1 7RU, UK
| | - Martin Rejzek
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
| | - Paul Brett
- Department of Metabolic Biology, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK
| | - Richard J B H N van den Berg
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2300 RA, Leiden, The Netherlands
| | - Johannes M F G Aerts
- Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands
| | - Hermen S Overkleeft
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg 55, 2300 RA, Leiden, The Netherlands
| | - Robert A Field
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK.
| |
Collapse
|
27
|
Peterschmitt MJ, Cox GF, Ibrahim J, MacDougall J, Underhill LH, Patel P, Gaemers SJ. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration. Blood Cells Mol Dis 2018; 68:185-191. [DOI: 10.1016/j.bcmd.2017.01.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Accepted: 01/12/2017] [Indexed: 11/16/2022]
|
28
|
Meanwell M, Sutherland M, Britton R. Application of sequential proline-catalyzed α-chlorination and aldol reactions in the total synthesis of 1-deoxygalactonojirimycin. CAN J CHEM 2018. [DOI: 10.1139/cjc-2017-0318] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A short enantioselective total synthesis of 1-deoxygalactonojirimycin (migalastat) has been achieved that does not rely on chiral pool starting materials or biocatalysis. Instead, this synthesis exploits a one-pot proline-catalyzed α-chlorination and aldol reaction of a commercially available aldehyde to assemble the entire carbon skeleton in a single step. The key role played by a nitrogen protecting group in the final epoxide opening reaction is highlighted as is the amenability to access structural analogues using this route.
Collapse
Affiliation(s)
- Michael Meanwell
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
| | - Mathew Sutherland
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
| | - Robert Britton
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
- Department of Chemistry, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
| |
Collapse
|
29
|
Iftikhar M, Fang Z. Modifications at the 6-O-position of 1-deoxynojirimycin: facile and efficient synthesis of 6-O-alkylated-N-octyl-1-deoxynojirimycin derivatives. J Carbohydr Chem 2017. [DOI: 10.1080/07328303.2017.1397683] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Mehwish Iftikhar
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu, P. R. China
| | - Zhijie Fang
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu, P. R. China
| |
Collapse
|
30
|
Gu X, Gupta V, Yang Y, Zhu JY, Carlson EJ, Kingsley C, Tash JS, Schönbrunn E, Hawkinson J, Georg GI. Structure-Activity Studies of N-Butyl-1-deoxynojirimycin (NB-DNJ) Analogues: Discovery of Potent and Selective Aminocyclopentitol Inhibitors of GBA1 and GBA2. ChemMedChem 2017; 12:1977-1984. [PMID: 28975712 PMCID: PMC5725710 DOI: 10.1002/cmdc.201700558] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Indexed: 12/26/2022]
Abstract
Analogues of N‐butyl‐1‐deoxynojirimycin (NB‐DNJ) were prepared and assayed for inhibition of ceramide‐specific glucosyltransferase (CGT), non‐lysosomal β‐glucosidase 2 (GBA2) and the lysosomal β‐glucosidase 1 (GBA1). Compounds 5 a–6 f, which carry sterically demanding nitrogen substituents, and compound 13, devoid of the C3 and C5 hydroxy groups present in DNJ/NB‐DGJ (N‐butyldeoxygalactojirimycin) showed no inhibitory activity for CGT or GBA2. Inversion of stereochemistry at C4 of N‐(n‐butyl)‐ and N‐(n‐nonyl)‐DGJ (compounds 24) also led to a loss of activity in these assays. The aminocyclopentitols N‐(n‐butyl)‐ (35 a), N‐(n‐nonyl)‐4‐amino‐5‐(hydroxymethyl)cyclopentane‐ (35 b), and N‐(1‐(pentyloxy)methyl)adamantan‐1‐yl)‐1,2,3‐triol (35 f), were found to be selective inhibitors of GBA1 and GBA2 that did not inhibit CGT (>1 mm), with the exception of 35 f, which inhibited CGT with an IC50 value of 1 mm. The N‐butyl analogue 35 a was 100‐fold selective for inhibiting GBA1 over GBA2 (Ki values of 32 nm and 3.3 μm for GBA1 and GBA2, respectively). The N‐nonyl analogue 35 b displayed a Ki value of ≪14 nm for GBA1 inhibition and a Ki of 43 nm for GBA2. The N‐(1‐(pentyloxy)methyl)adamantan‐1‐yl) derivative 35 f had Ki values of ≈16 and 14 nm for GBA1 and GBA2, respectively. The related N‐bis‐substituted aminocyclopentitols were found to be significantly less potent inhibitors than their mono‐substituted analogues. The aminocyclopentitol scaffold should hold promise for further inhibitor development.
Collapse
Affiliation(s)
- Xingxian Gu
- Department of Medicinal Chemistry, University of Kansas, Lawrence, KS, 66045, USA.,Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, 55414, USA
| | | | - Yan Yang
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Jin-Yi Zhu
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Erick J Carlson
- Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, 55414, USA
| | - Carolyn Kingsley
- Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, 55414, USA
| | - Joseph S Tash
- University of Kansas Medical Center, Kansas City, KS, 66160, USA
| | - Ernst Schönbrunn
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, 33612, USA
| | - Jon Hawkinson
- Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, 55414, USA
| | - Gunda I Georg
- Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, MN, 55414, USA
| |
Collapse
|
31
|
Marjanovic Trajkovic J, Milanovic V, Ferjancic Z, Saicic RN. On the Asymmetric Induction in Proline-Catalyzed Aldol Reactions: Reagent-Controlled Addition Reactions of 2,2-Dimethyl-1,3-dioxane-5-one to Acyclic Chiral α-Branched Aldehydes. European J Org Chem 2017. [DOI: 10.1002/ejoc.201701073] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Affiliation(s)
| | - Vesna Milanovic
- Faculty of Chemistry; University of Belgrade; Studentski trg 16, POB 51 11158 Belgrade 118 Serbia
| | - Zorana Ferjancic
- Faculty of Chemistry; University of Belgrade; Studentski trg 16, POB 51 11158 Belgrade 118 Serbia
| | - Radomir N. Saicic
- Faculty of Chemistry; University of Belgrade; Studentski trg 16, POB 51 11158 Belgrade 118 Serbia
- Serbian Academy of Sciences and Arts; Knez Mihailova 35 11000 Belgrade Serbia
| |
Collapse
|
32
|
Lahav D, Liu B, van den Berg RJBHN, van den
Nieuwendijk AMCH, Wennekes T, Ghisaidoobe AT, Breen I, Ferraz MJ, Kuo CL, Wu L, Geurink PP, Ovaa H, van der Marel GA, van der Stelt M, Boot RG, Davies GJ, Aerts JMFG, Overkleeft HS. A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selective Inhibitors for Human Nonlysosomal Glucosylceramidase. J Am Chem Soc 2017; 139:14192-14197. [PMID: 28937220 PMCID: PMC5677758 DOI: 10.1021/jacs.7b07352] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Indexed: 11/28/2022]
Abstract
Human nonlysosomal glucosylceramidase (GBA2) is one of several enzymes that controls levels of glycolipids and whose activity is linked to several human disease states. There is a major need to design or discover selective GBA2 inhibitors both as chemical tools and as potential therapeutic agents. Here, we describe the development of a fluorescence polarization activity-based protein profiling (FluoPol-ABPP) assay for the rapid identification, from a 350+ library of iminosugars, of GBA2 inhibitors. A focused library is generated based on leads from the FluoPol-ABPP screen and assessed on GBA2 selectivity offset against the other glucosylceramide metabolizing enzymes, glucosylceramide synthase (GCS), lysosomal glucosylceramidase (GBA), and the cytosolic retaining β-glucosidase, GBA3. Our work, yielding potent and selective GBA2 inhibitors, also provides a roadmap for the development of high-throughput assays for identifying retaining glycosidase inhibitors by FluoPol-ABPP on cell extracts containing recombinant, overexpressed glycosidase as the easily accessible enzyme source.
Collapse
Affiliation(s)
- Daniël Lahav
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Bing Liu
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Richard J. B. H. N. van den Berg
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Adrianus M. C. H. van den
Nieuwendijk
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Tom Wennekes
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Amar T. Ghisaidoobe
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Imogen Breen
- Structural
Biology Laboratory, Department of Chemistry, The University of York, York YO10 5DD, United Kingdom
| | - Maria J. Ferraz
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Chi-Lin Kuo
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Liang Wu
- Structural
Biology Laboratory, Department of Chemistry, The University of York, York YO10 5DD, United Kingdom
| | - Paul P. Geurink
- Department of Chemical Immunology, Leiden
University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands
| | - Huib Ovaa
- Department of Chemical Immunology, Leiden
University Medical Center, Einthovenweg 20, 2333 ZC Leiden, The Netherlands
| | - Gijsbert A. van der Marel
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Mario van der Stelt
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Rolf G. Boot
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Gideon J. Davies
- Structural
Biology Laboratory, Department of Chemistry, The University of York, York YO10 5DD, United Kingdom
| | - Johannes M. F. G. Aerts
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| | - Herman S. Overkleeft
- Bioorganic
Synthesis, Molecular Physiology, and Medical Biochemistry, Leiden
Institute of Chemistry, Leiden University, Einsteinweg 55, 2333
CC Leiden, The Netherlands
| |
Collapse
|
33
|
Iftikhar M, Wang L, Fang Z. Synthesis of 1-Deoxynojirimycin: Exploration of Optimised Conditions for Reductive Amidation and Separation of Epimers. JOURNAL OF CHEMICAL RESEARCH 2017. [DOI: 10.3184/174751917x15000341607489] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
1-Deoxynojirimycin (DNJ), which has importance with respect to sugar processing enzymes, is a synthetic target for chemists. A key step in the synthesis of DNJ is the preparation of 2,3,4,6-tetra- O-benzyl-D-glucono-δ-lactam. By varying reaction parameters such as temperature, solvent and reducing reagent, improvements on previous methods are described. A novel approach for the synthesis of 2,3,4,6-tetra- O-benzyl-5-dehydro-5-deoxo-D-gluconamide has been developed by using PCC as an oxidising agent. Separation of epimers permitted DNJ to be obtained in 85% yield after reduction and hydrogenolysis steps.
Collapse
Affiliation(s)
- Mehwish Iftikhar
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu 210094, P.R. China
| | - Lin Wang
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu 210094, P.R. China
| | - Zhijie Fang
- School of Chemical Engineering, Nanjing University of Science & Technology, Nanjing, Jiangsu 210094, P.R. China
| |
Collapse
|
34
|
Hamler R, Brignol N, Clark SW, Morrison S, Dungan LB, Chang HH, Khanna R, Frascella M, Valenzano KJ, Benjamin ER, Boyd RE. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease. Anal Chem 2017; 89:8288-8295. [PMID: 28686011 DOI: 10.1021/acs.analchem.7b01442] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Gaucher disease (GD) is caused by mutations in the GBA1 gene that encodes the lysosomal enzyme acid β-glucosidase (GCase). Reduced GCase activity primarily leads to the accumulation of two substrates, glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph). Current treatment options have not been shown to ameliorate the neurological pathology observed in the most severe forms of GD, clearly representing an unmet medical need. To better understand the relationship between GlcCer and GlcSph accumulation and ultimately their connection with the progression of neurological pathology, we developed LC-MS/MS methods to quantify GlcCer and GlcSph in mouse brain tissue. A significant challenge in developing these methods was the chromatographic separation of GlcCer and GlcSph from the far more abundant isobaric galactosyl epimers naturally occurring in white matter. After validation of both methods, we evaluated the levels of both substrates in five different GD mouse models, and found significant elevation of brain GlcSph in all five, while GlcCer was elevated in only one of the five models. In addition, we measured GlcCer and GlcSph levels in the brains of wild-type mice after administration of the GCase inhibitor conduritol β-epoxide (CBE), as well as the nonlysosomal β-glucosidase (GBA2) inhibitor N-butyldeoxygalactonojirimycin (NB-DGJ). Inhibition of GCase by CBE resulted in elevation of both sphingolipids; however, inhibition of GBA2 by NB-DGJ resulted in elevation of GlcCer only. Taken together, these data support the idea that GlcSph is a more selective and sensitive biomarker than GlcCer for neuronopathic GD in preclinical models.
Collapse
Affiliation(s)
- Rick Hamler
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Nastry Brignol
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Sean W Clark
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Sean Morrison
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Leo B Dungan
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Hui H Chang
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Richie Khanna
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Michelle Frascella
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Kenneth J Valenzano
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Elfrida R Benjamin
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| | - Robert E Boyd
- Amicus Therapeutics, Inc. , 1 Cedar Brook Drive, Cranbury, New Jersey 08512, United States
| |
Collapse
|
35
|
Beenakker TM, Wander DPA, Offen WA, Artola M, Raich L, Ferraz MJ, Li KY, Houben JHPM, van Rijssel ER, Hansen T, van der Marel GA, Codée JDC, Aerts JMF, Rovira C, Davies GJ, Overkleeft HS. Carba-cyclophellitols Are Neutral Retaining-Glucosidase Inhibitors. J Am Chem Soc 2017; 139:6534-6537. [PMID: 28463498 PMCID: PMC5437670 DOI: 10.1021/jacs.7b01773] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 01/15/2023]
Abstract
The conformational analysis of glycosidases affords a route to their specific inhibition through transition-state mimicry. Inspired by the rapid reaction rates of cyclophellitol and cyclophellitol aziridine-both covalent retaining β-glucosidase inhibitors-we postulated that the corresponding carba "cyclopropyl" analogue would be a potent retaining β-glucosidase inhibitor for those enzymes reacting through the 4H3 transition-state conformation. Ab initio metadynamics simulations of the conformational free energy landscape for the cyclopropyl inhibitors show a strong bias for the 4H3 conformation, and carba-cyclophellitol, with an N-(4-azidobutyl)carboxamide moiety, proved to be a potent inhibitor (Ki = 8.2 nM) of the Thermotoga maritima TmGH1 β-glucosidase. 3-D structural analysis and comparison with unreacted epoxides show that this compound indeed binds in the 4H3 conformation, suggesting that conformational strain induced through a cyclopropyl unit may add to the armory of tight-binding inhibitor designs.
Collapse
Affiliation(s)
- Thomas
J. M. Beenakker
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Dennis P. A. Wander
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Wendy A. Offen
- Department
of Chemistry, University of York, Heslington, York, YO10
5DD, U.K.
| | - Marta Artola
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Lluís Raich
- Departament
de Química Inorgànica i Orgànica (Secció
de Química Orgànica) & Institut de Quimica Teòrica
i Computacional (IQTCUB), Universitat de
Barcelona, Martí
i Franquès 1, 08028 Barcelona, Spain
| | - Maria J. Ferraz
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Kah-Yee Li
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Judith H. P. M. Houben
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Erwin R. van Rijssel
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Thomas Hansen
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Gijsbert A. van der Marel
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Jeroen D. C. Codée
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Johannes M. F.
G. Aerts
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| | - Carme Rovira
- Departament
de Química Inorgànica i Orgànica (Secció
de Química Orgànica) & Institut de Quimica Teòrica
i Computacional (IQTCUB), Universitat de
Barcelona, Martí
i Franquès 1, 08028 Barcelona, Spain
- Institució
Catalana de Recerca i Estudis Avançats (ICREA), 08020 Barcelona, Spain
| | - Gideon J. Davies
- Department
of Chemistry, University of York, Heslington, York, YO10
5DD, U.K.
| | - Herman S. Overkleeft
- Department
of Bio-organic Synthesis and Department of Medical Biochemistry,
Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands
| |
Collapse
|
36
|
Lalazar G, Zigmond E, Weksler-Zangen S, Ya'acov AB, Levy MS, Hemed N, Raz I, Ilan Y. Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. J Med Food 2017; 20:458-464. [DOI: 10.1089/jmf.2016.3753] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Affiliation(s)
- Gadi Lalazar
- Gasroeterology and Liver Units, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Ehud Zigmond
- Gasroeterology and Liver Units, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Sarah Weksler-Zangen
- Diabetes Unit, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Ami Ben Ya'acov
- Gasroeterology and Liver Units, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Miriam Sklair Levy
- Department of Radiology, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Nilla Hemed
- Gasroeterology and Liver Units, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Itamar Raz
- Diabetes Unit, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| | - Yaron Ilan
- Gasroeterology and Liver Units, Department of Medicine, Hebrew University-Hadassah Medical Center, Jerusalem, Israel
| |
Collapse
|
37
|
One pot oxidative dehydration - oxidation of polyhydroxyhexanal oxime to polyhydroxy oxohexanenitrile: A versatile methodology for the facile access of azasugar alkaloids. Carbohydr Res 2016; 435:1-6. [DOI: 10.1016/j.carres.2016.09.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Revised: 09/05/2016] [Accepted: 09/06/2016] [Indexed: 12/21/2022]
|
38
|
Witkowski G, Kowalski M, Szyszka Ł, Potopnyk MA, Jarosz S. Synthesis of 5-epi-deoxynojirimycin from methyl α-d-glucoside. ACTA ACUST UNITED AC 2016. [DOI: 10.1016/j.tetasy.2016.06.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
39
|
Kim JS, Lee YT, Lee KH, Myeong IS, Kang JC, Jung C, Park SH, Ham WH. Stereoselective Chirality Extension of syn,anti- and syn,syn-Oxazine and Stereochemical Analysis of Chiral 1,3-Oxazines: Stereoselective Total Syntheses of (+)-1-Deoxygalactonojirimycin and (−)-1-Deoxygulonojirimycin. J Org Chem 2016; 81:7432-8. [DOI: 10.1021/acs.joc.6b01079] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jin-Seok Kim
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - Yong-Taek Lee
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - Kun-Hee Lee
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - In-Soo Myeong
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - Jong-Cheol Kang
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - Changyoung Jung
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - Seok-Hwi Park
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| | - Won-Hun Ham
- School
of Pharmacy, Sungkyunkwan University, Seobu-ro 2066, Suwon-si, Gyeonggi-do 16419, Republic of Korea
| |
Collapse
|
40
|
Ilan Y. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2016; 310:G1102-17. [PMID: 27173510 DOI: 10.1152/ajpgi.00095.2016] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2016] [Accepted: 05/04/2016] [Indexed: 01/31/2023]
Abstract
The compounds of sphingomyelin-ceramide-glycosphingolipid pathways have been studied as potential secondary messenger molecules in various systems, along with liver function and insulin resistance. Secondary messenger molecules act directly or indirectly to affect cell organelles and intercellular interactions. Their potential role in the pathogenesis of steatohepatitis and diabetes has been suggested. Data samples collected from patients with Gaucher's disease, who had high levels of glucocerebroside, support a role for compounds from these pathways as a messenger molecules in the pathogenesis of fatty liver disease and diabetes. The present review summarizes some of the recent data on the role of glycosphingolipid molecules as messenger molecules in various physiological and pathological conditions, more specifically including insulin resistance and fatty liver disease.
Collapse
Affiliation(s)
- Yaron Ilan
- Gastroenterology and Liver Units, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
| |
Collapse
|
41
|
Sultana S, Truong NY, Vieira DB, Wigger JGD, Forrester AM, Veinotte CJ, Berman JN, van der Spoel AC. Characterization of the Zebrafish Homolog of β-Glucosidase 2: A Target of the Drug Miglustat. Zebrafish 2016; 13:177-87. [PMID: 26909767 DOI: 10.1089/zeb.2015.1152] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
The small-molecular compound miglustat (N-butyldeoxynojirimycin, Zavesca(®)) has been approved for clinical use in type 1 Gaucher disease and Niemann-Pick type C disease, which are disorders caused by dysfunction of the endosomal-autophagic-lysosomal system. Miglustat inhibits a number of enzymes involved in glycoconjugate and glycan metabolism, including β-glucosidase 2 (GBA2), which is exceptionally sensitive to inhibition by miglustat. GBA2 is a glucosylceramide-degrading enzyme that is located on the plasma membrane/endoplasmic reticulum, and is distinct from the lysosomal enzyme glucocerebrosidase (GBA). Various strands of evidence suggest that inhibition of GBA2 contributes to the therapeutic benefits of miglustat. To further explore the pharmacology and biology of GBA2, we investigated whether the zebrafish homolog of GBA2 has similar enzymatic properties and pharmacological sensitivities to its human counterpart. We established that zebrafish has endogenous β-glucosidase activity toward lipid- and water-soluble GBA2 substrates, which can be inhibited by miglustat, N-butyldeoxygalactonojirimycin, and conduritol B epoxide. β-Glucosidase activities with highly similar characteristics were expressed in cells transfected with the zebrafish gba2 cDNA and in cells transfected with the human GBA2 cDNA. These results provide a foundation for the use of zebrafish in screening GBA2-targeting molecules, and for wider studies investigating GBA2 biology.
Collapse
Affiliation(s)
- Saki Sultana
- 1 Department of Pediatrics, Atlantic Research Centre, Dalhousie University , Halifax, Canada .,2 Department of Biochemistry and Molecular Biology, Atlantic Research Centre, Dalhousie University , Halifax, Canada
| | - Nhu Y Truong
- 1 Department of Pediatrics, Atlantic Research Centre, Dalhousie University , Halifax, Canada
| | - Douglas B Vieira
- 1 Department of Pediatrics, Atlantic Research Centre, Dalhousie University , Halifax, Canada
| | - Jasper G D Wigger
- 1 Department of Pediatrics, Atlantic Research Centre, Dalhousie University , Halifax, Canada
| | - A Michael Forrester
- 3 Department of Microbiology and Immunology, Dalhousie University , Halifax, Canada
| | - Chansey J Veinotte
- 3 Department of Microbiology and Immunology, Dalhousie University , Halifax, Canada
| | - Jason N Berman
- 3 Department of Microbiology and Immunology, Dalhousie University , Halifax, Canada .,4 Department of Pediatrics, IWK Health Centre, Dalhousie University , Halifax, Canada .,5 Department of Pathology, Dalhousie University , Halifax, Canada
| | - Aarnoud C van der Spoel
- 1 Department of Pediatrics, Atlantic Research Centre, Dalhousie University , Halifax, Canada .,2 Department of Biochemistry and Molecular Biology, Atlantic Research Centre, Dalhousie University , Halifax, Canada
| |
Collapse
|
42
|
Zhao K, Zhou G, Nie H, Chen W. Three-step synthesis of l-ido-1-deoxynojirimycin derivatives by reductive amination in water, “borrowing hydrogen” under neat conditions and deprotection. Org Biomol Chem 2016; 14:9466-9471. [DOI: 10.1039/c6ob01864e] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A three-step synthesis of l-ido-1-deoxynojirimycin derivatives, starting from readily available 2,3,4,6-tetra-O-benzyl-d-glucopyranose via Ir-catalyzed reductive amination in water, “borrowing hydrogen” under neat conditions, and Pd-catalyzed debenzylation, is reported.
Collapse
Affiliation(s)
- Kai Zhao
- School of Pharmacy
- Fourth Military Medical University
- Xian
- P. R. China
| | - Gang Zhou
- School of Pharmacy
- Fourth Military Medical University
- Xian
- P. R. China
| | - Huifang Nie
- School of Pharmacy
- Fourth Military Medical University
- Xian
- P. R. China
| | - Weiping Chen
- School of Pharmacy
- Fourth Military Medical University
- Xian
- P. R. China
| |
Collapse
|
43
|
van den Berg RJBHN, van Rijssel ER, Ferraz MJ, Houben J, Strijland A, Donker-Koopman WE, Wennekes T, Bonger KM, Ghisaidoobe ABT, Hoogendoorn S, van der Marel GA, Codée JDC, Overkleeft HS, Aerts JMFG. Synthesis and Evaluation of Hybrid Structures Composed of Two Glucosylceramide Synthase Inhibitors. ChemMedChem 2015; 10:2042-62. [DOI: 10.1002/cmdc.201500407] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Indexed: 01/08/2023]
Affiliation(s)
| | - Erwin R. van Rijssel
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Maria Joao Ferraz
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Judith Houben
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Anneke Strijland
- Department of Medical Biochemistry; Academic Medical Center; University of Amsterdam; Meibergdreef 9 1105 AZ Amsterdam The Netherlands
| | - Wilma E. Donker-Koopman
- Department of Medical Biochemistry; Academic Medical Center; University of Amsterdam; Meibergdreef 9 1105 AZ Amsterdam The Netherlands
| | - Tom Wennekes
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
- Laboratory of Organic Chemistry; Wageningen University; Dreijenplein 8 6703 HB Wageningen The Netherlands
| | - Kimberly M. Bonger
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Amar B. T. Ghisaidoobe
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Sascha Hoogendoorn
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Gijsbert A. van der Marel
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Jeroen D. C. Codée
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Herman S. Overkleeft
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
| | - Johannes M. F. G. Aerts
- Leiden Institute of Chemistry; Leiden University; Gorlaeus Laboratories; Einsteinweg 55 2300 RA Leiden The Netherlands
- Department of Medical Biochemistry; Academic Medical Center; University of Amsterdam; Meibergdreef 9 1105 AZ Amsterdam The Netherlands
| |
Collapse
|
44
|
Park SH, Kim JY, Kim JS, Jung C, Song DK, Ham WH. 1,3-Oxazine as a chiral building block used in the total synthesis of (+)-1-deoxynojirimycin and (2R,5R)-dihydroxymethyl-(3R,4R)-dihydroxypyrrolidine. ACTA ACUST UNITED AC 2015. [DOI: 10.1016/j.tetasy.2015.05.008] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
45
|
Hoogendoorn S, Mock ED, Strijland A, Donker-Koopman WE, van den Elst H, van den Berg RJBHN, Aerts JMFG, van der Marel GA, Overkleeft HS. ortho-Carborane-ModifiedN-Substituted Deoxynojirimycins. European J Org Chem 2015. [DOI: 10.1002/ejoc.201500364] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
46
|
Zelli R, Longevial JF, Dumy P, Marra A. Synthesis and biological properties of multivalent iminosugars. NEW J CHEM 2015. [DOI: 10.1039/c5nj00462d] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Clustering 1-deoxynojirimycin (DNJ), first isolated from white mulberry, and other iminosugars around various scaffolds gave strong glycosidase inhibitors.
Collapse
Affiliation(s)
- Renaud Zelli
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247
- Université de Montpellier
- Ecole Nationale Supérieure de Chimie de Montpellier
- 34296 Montpellier cedex 5
| | - Jean-François Longevial
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247
- Université de Montpellier
- Ecole Nationale Supérieure de Chimie de Montpellier
- 34296 Montpellier cedex 5
| | - Pascal Dumy
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247
- Université de Montpellier
- Ecole Nationale Supérieure de Chimie de Montpellier
- 34296 Montpellier cedex 5
| | - Alberto Marra
- Institut des Biomolécules Max Mousseron (IBMM)
- UMR 5247
- Université de Montpellier
- Ecole Nationale Supérieure de Chimie de Montpellier
- 34296 Montpellier cedex 5
| |
Collapse
|
47
|
Schiffmann R. The consequences of genetic and pharmacologic reduction in sphingolipid synthesis. J Inherit Metab Dis 2015; 38:77-84. [PMID: 25164785 DOI: 10.1007/s10545-014-9758-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 07/28/2014] [Accepted: 07/31/2014] [Indexed: 10/24/2022]
Abstract
A new therapy based on substrate synthesis reduction in sphingolipidoses is showing promise. The consequences of decreasing sphingolipid synthesis depend on the level at which synthetic blockage occurs and on the extent of the blockage. Complete synthetic blockage may be lethal if it includes all sphingolipids, such as in a global knockout of serine palmitoyltransferase. Partial inhibition of sphingolipid synthetic pathways is usually benign and may have beneficial effects in a number of lysosomal diseases and in more common pathologies, as seen in animal models for atherosclerosis, polycystic kidney disease, diabetes, and asthma. Studies of various forms of sphingolipid synthesis reduction serve to highlight not only the cellular role of these lipids but also the potential risks and therapeutic benefits of pharmacological agents to be used in therapy for human diseases.
Collapse
Affiliation(s)
- Raphael Schiffmann
- Institute of Metabolic Disease, Baylor Research Institute, 3812 Elm Street, Dallas, TX, USA,
| |
Collapse
|
48
|
Ghisaidoobe AT, van den Berg RJBHN, Butt SS, Strijland A, Donker-Koopman WE, Scheij S, van den Nieuwendijk AMCH, Koomen GJ, van Loevezijn A, Leemhuis M, Wennekes T, van der Stelt M, van der Marel GA, van Boeckel CAA, Aerts JMFG, Overkleeft HS. Identification and Development of Biphenyl Substituted Iminosugars as Improved Dual Glucosylceramide Synthase/Neutral Glucosylceramidase Inhibitors. J Med Chem 2014; 57:9096-104. [DOI: 10.1021/jm501181z] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Amar T. Ghisaidoobe
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
| | | | - Saleem S. Butt
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
| | - Anneke Strijland
- Department of Medical Biochemistry,
Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
| | - Wilma E. Donker-Koopman
- Department of Medical Biochemistry,
Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
| | - Saskia Scheij
- Department of Medical Biochemistry,
Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
| | | | - Gerrit-Jan Koomen
- van
‘t Hoff Institute for Molecular Sciences, University of Amsterdam, , P.O. Box
94157, 1090 GD Amsterdam, The Netherlands
| | - Arnold van Loevezijn
- van
‘t Hoff Institute for Molecular Sciences, University of Amsterdam, , P.O. Box
94157, 1090 GD Amsterdam, The Netherlands
| | - Mark Leemhuis
- van
‘t Hoff Institute for Molecular Sciences, University of Amsterdam, , P.O. Box
94157, 1090 GD Amsterdam, The Netherlands
| | - Tom Wennekes
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
| | - Mario van der Stelt
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
| | - Gijsbert A. van der Marel
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
| | - Constant A. A. van Boeckel
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
- Pivot Park Screening
Centre, Molenstraat 110, 5342 CC Oss, The Netherlands
| | - Johannes M. F. G. Aerts
- Department of Medical Biochemistry,
Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
| | - Herman S. Overkleeft
- Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, Einsteinweg
55, 2300 RA Leiden, The Netherlands
| |
Collapse
|
49
|
Loberto N, Tebon M, Lampronti I, Marchetti N, Aureli M, Bassi R, Giri MG, Bezzerri V, Lovato V, Cantù C, Munari S, Cheng SH, Cavazzini A, Gambari R, Sonnino S, Cabrini G, Dechecchi MC. GBA2-encoded β-glucosidase activity is involved in the inflammatory response to Pseudomonas aeruginosa. PLoS One 2014; 9:e104763. [PMID: 25141135 PMCID: PMC4139313 DOI: 10.1371/journal.pone.0104763] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Accepted: 07/16/2014] [Indexed: 11/19/2022] Open
Abstract
Current anti-inflammatory strategies for the treatment of pulmonary disease in cystic fibrosis (CF) are limited; thus, there is continued interest in identifying additional molecular targets for therapeutic intervention. Given the emerging role of sphingolipids (SLs) in various respiratory disorders, including CF, drugs that selectively target the enzymes associated with SL metabolism are under development. Miglustat, a well-characterized iminosugar-based inhibitor of β-glucosidase 2 (GBA2), has shown promise in CF treatment because it reduces the inflammatory response to infection by P. aeruginosa and restores F508del-CFTR chloride channel activity. This study aimed to probe the molecular basis for the anti-inflammatory activity of miglustat by examining specifically the role of GBA2 following the infection of CF bronchial epithelial cells by P. aeruginosa. We also report the anti-inflammatory activity of another potent inhibitor of GBA2 activity, namely N-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (Genz-529648). In CF bronchial cells, inhibition of GBA2 by miglustat or Genz-529648 significantly reduced the induction of IL-8 mRNA levels and protein release following infection by P. aeruginosa. Hence, the present data demonstrate that the anti-inflammatory effects of miglustat and Genz-529648 are likely exerted through inhibition of GBA2.
Collapse
Affiliation(s)
- Nicoletta Loberto
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Maela Tebon
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Ilaria Lampronti
- Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy
| | - Nicola Marchetti
- Department of Chemistry and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy
| | - Massimo Aureli
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Rosaria Bassi
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Maria Grazia Giri
- Medical Physics Unit, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Valentino Bezzerri
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Valentina Lovato
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Cinzia Cantù
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Silvia Munari
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Seng H. Cheng
- Genzyme, a Sanofi Company, Framingham, Massachusetts, United States of America
| | - Alberto Cavazzini
- Department of Chemistry and Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy
| | - Roberto Gambari
- Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy
| | - Sandro Sonnino
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - Giulio Cabrini
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| | - Maria Cristina Dechecchi
- Laboratory of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, Verona, Italy
| |
Collapse
|
50
|
Chavan SP, Dumare NB, Pawar KP. A novel, concise and efficient protocol for non-natural piperidine compounds. RSC Adv 2014. [DOI: 10.1039/c4ra04558k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|